ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 7 for:    Edmonston Strain of Measles Virus,

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03456908
Recruitment Status : Enrolling by invitation
First Posted : March 7, 2018
Last Update Posted : March 21, 2018
Sponsor:
Information provided by (Responsible Party):
Timothy R. DeGrado, Ph.D., Mayo Clinic

Brief Summary:
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .

Condition or disease Intervention/treatment Phase
Myeloma Before MV-NIS Treatment Endometrial Cancer Before VSV-hINF-NIS Treatment Combination Product: 18F-TFB-PET Phase 1 Phase 2

Detailed Description:
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. Imaging of functional hNIS activity in tissues with [18F]BF4 is anticipated to provide superior sensitivity and image quality to Tc-99m SPECT for monitoring hNIS transduction effected by viral therapies. The proposed work is designed to 1) evaluate the imaging feasibility in comparison with Tc-99m SPECT of hNIS expression in a) 10 myeloma patients treated with Edmonston Measles virus-NIS (MV-NIS) and b) 10 endometrial cancer patients treated with vesicular stomatitis virus engineered to express human interferon-and NIS (VSV-hINF-NIS). This data will be necessary to support future regulatory submissions.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies
Actual Study Start Date : March 16, 2018
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: myeloma before MV-NIS treatment
Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: "Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma",
Combination Product: 18F-TFB-PET
Infusion of F-18 TFB and PET / CT imaging

Experimental: endometrial cancer before VSV-hINF-NIS treatment
Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer", IRB 15-007000
Combination Product: 18F-TFB-PET
Infusion of F-18 TFB and PET / CT imaging




Primary Outcome Measures :
  1. Evaluate the uptake and distribution of the imaging agent 18F-TFB [ Time Frame: up to 10 days ]
    This is a preliminary study and all analyses will be exploratory in nature.


Secondary Outcome Measures :
  1. Imaging Sensitivities [ Time Frame: up to 10 days ]
    Comparisons will be made between 18F -TFB-PET/CT scans and 99mTc-SPECT/CT scans for feasibility to monitor expression of NIS in tumors following oncoviral treatments in the subjects



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Myeloma Patients

  1. Patients who are currently participating in Mayo Clinic MV-NIS trial (IRB: 06-005263) and agree to enroll in additional 18F-TFB PET studies.
  2. Subjects are greater than 21 years of age.
  3. Subjects must provide written informed consent.
  4. Agree to provide biopsy of tumor indicated on PET for research purposes, if accessible.

Endometrial Cancer Patients

1 Patients who are currently participating in Mayo Clinic VSV-hINF-NIS trial (IRB 15-007000) and agree to enroll in additional 18F -TFB-PET studies.

2. Subjects are greater than 21 years of age. 3. Subjects must provide written informed consent. 4. Agree to provide biopsy of tumor indicated on PET for research purposes, if accessible.

Exclusion Criteria:

Myeloma Patients

Patients with any of the following are ineligible to enroll in this study:

  1. Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:

    1. Cardiac surgery or myocardial infarction within the last 6 months.
    2. Unstable angina.
    3. Coronary artery disease that required a change in medication within the last 3 months.
    4. Decompensated congestive heart failure.
    5. Significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status.
    6. Severe mitral or aortic valvular disease.
    7. Uncontrolled high blood pressure.
    8. Congenital heart disease. Before enrolling a patient with any of the above conditions, the co- investigator must contact the principal investigator.
  2. History of drug or alcohol abuse within the last year, or prior prolonged history of abuse.
  3. Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2.
  4. Women of childbearing potential must not be pregnant (negative urine β-HCG at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of 18F-TFB PET unless the screening urine pregnancy test falls within 48 hours of injection.
  5. Patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type.
  6. History of severe drug allergy or hypersensitivity.
  7. Patients who had received an investigational medication within the last 30 days or who have participated in a clinical trial involving medications other than the related MV-NIS or VSV-NIS viruses in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication.
  8. Patients with current clinically significant medical comorbidities that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication, or limit interpretation of the study results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer, HIV infection and AIDS.
  9. Patients who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies.

Endometrial Cancer Patients

Patients with any of the following are ineligible to enroll in this study:

  1. Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:

    1. Cardiac surgery or myocardial infarction within the last 6 months.
    2. Unstable angina.
    3. Coronary artery disease that required a change in medication within the last 3 months.
    4. Decompensated congestive heart failure.
    5. Significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status.
    6. Severe mitral or aortic valvular disease.
    7. Uncontrolled high blood pressure.
    8. Congenital heart disease. Before enrolling a patient with any of the above conditions, the co- investigator must contact the principal investigator.
  2. History of drug or alcohol abuse within the last year, or prior prolonged history of abuse.
  3. Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2.
  4. Women of childbearing potential must not be pregnant (negative urine β-HCG at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of 18F-TFB PET unless the screening urine pregnancy test falls within 48 hours of injection.
  5. Patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type.
  6. History of severe drug allergy or hypersensitivity.
  7. Patients who had received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication.
  8. Patients with current clinically significant medical comorbidities, that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication or limit interpretation of the study results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer, HIV infection and AIDS.
  9. Patients who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03456908


Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Timothy R DeGrado, PhD Mayo Clinic

Responsible Party: Timothy R. DeGrado, Ph.D., Professor of Radiology, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03456908     History of Changes
Other Study ID Numbers: F18 17-008847
First Posted: March 7, 2018    Key Record Dates
Last Update Posted: March 21, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: N/A no plan to share IPD

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female